NeuroAD Therapy System is undergoing further clinical studies.
To learn more about additional sites in other locations throughout the world, or for more information about participating in a clinical trial, please contact Neuronix at email@example.com
A recent multi-site clinical trial, conducted in USA and Israel was completed. Results will be presented in the coming CTAD Conference (Dec. 9th, 2016, San Diego).
CTAD 2016 Program
ORAL COMMUNICATIONS SESSION
OC34 - Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients: Results of Medical Device Pivotal Multi-Center Study Marwan N. Sabbagh MD1 ; Alvaro Pascual-Leone; MD PhD2 ; Carl H. Sadowsky, MD3 ; Babak Tousi, MD4 ; Marc E. Agronin, MD5 ; Gustavo Alva, MD6 ; Carmel Armon, MD7 ; Charles Bernick, MD8 ; Andrew P. Keegan, MD9 ; Stella Karantzoulis, PhD10
(1) Barrow Neurological Institute, Phoenix AZ USA, (2) Berenson-Allen Center for Noninvasive Brain Stimulation and Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, MA, (3) Department of Neurology, Nova SE University, Ft Lauderdale, FL, (4) Lou Ruvo Center for Brain Health Cleveland Clinic, Neurological Institute, Cleveland, OH, (5) Mental Health and Clinical Research, Miami Jewish Health Systems, Miami, FL, (6) ATP Clinical Research, Costa Mesa, CA, (7) Department of Neurology, Assaf Harofeh Medical Center, Zerifin, Israel, (8) Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, (9) Roskamp Institute Clinic, Sarasota, FL, (10) Alzheimer’s Disease Center, Center for Cognitive Neurology, New York University Langone Medical Center, New York, NY
neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.